Baltzer Pascal A T, Bennani-Baiti Barbara, Stöttinger Alexander, Bumberger Alexander, Kapetas Panagiotis, Clauser Paola
Department of Biomedical Imaging and Image-guided Therapy, Allgemeines Krankenhaus, Medizinische Universität Wien, Austria.
Department of Biomedical Imaging and Image-guided Therapy, Allgemeines Krankenhaus, Medizinische Universität Wien, Austria.
Magn Reson Imaging. 2018 Feb;46:70-74. doi: 10.1016/j.mri.2017.10.012. Epub 2017 Nov 6.
Microcalcifications are a common finding in mammography and usually require invasive procedures to diagnose or exclude malignancy. As many microcalcifications are due to benign lesions, we wanted to assess whether breast MRI as an additional diagnostic tool may be used to distinguish benign from malignant in this setting.
Eligible for this retrospective, IRB-approved observational study were 858 consecutive patients (mean age 54±11years) undergoing stereotactically-guided biopsies of suspicious mammographic microcalcifications during three year at our institution. Finally included were 152 patients who also underwent breast MRI <8weeks prior to biopsy. In case of malignant or lesions of uncertain malignant potential, subsequent surgery was performed. Benign findings were confirmed by imaging follow-up. BI-RADS category assignments from the original mammography and breast MRI reports were compared to the final diagnosis (benign vs. malignant) to determine diagnostic benchmarks.
Histopathology revealed 81 benign (53.3%), 41 DCIS (27%) and 30 (19.7%) invasive cancers. Sensitivity, specificity, positive and negative predictive values for breast MRI were 97.2% (69/71), 39.5% (32/81), 58.5% (69/118) and 94.1% (32/34), respectively. Thus, 32/81 unnecessary biopsies in benign lesions (39.5%) may have been avoided, missing 2/71 malignant lesions (2.8%), both DCIS G2.
Breast MRI as an additional diagnostic tool can be used to accurately distinguish benign from malignant mammographic microcalcifications and may thus be helpful to reduce unnecessary breast biopsies.
微钙化是乳腺钼靶检查中常见的表现,通常需要进行侵入性检查来诊断或排除恶性病变。由于许多微钙化是由良性病变引起的,我们想评估乳腺磁共振成像(MRI)作为一种额外的诊断工具,在这种情况下是否可用于区分良性和恶性病变。
本项回顾性、经机构审查委员会批准的观察性研究纳入了858例连续患者(平均年龄54±11岁),这些患者在三年间于我院接受了乳腺钼靶可疑微钙化的立体定向活检。最终纳入152例在活检前8周内还接受了乳腺MRI检查的患者。对于恶性或恶性潜能不确定的病变,随后进行了手术。良性结果通过影像学随访得以证实。将原始乳腺钼靶和乳腺MRI报告中的BI-RADS分类与最终诊断(良性与恶性)进行比较,以确定诊断基准。
组织病理学显示81例良性病变(53.3%)、41例导管原位癌(DCIS,27%)和30例浸润性癌(19.7%)。乳腺MRI的敏感性、特异性、阳性预测值和阴性预测值分别为97.2%(69/71)、39.5%(32/81)、58.5%(69/118)和94.1%(32/34)。因此,可能避免了81例良性病变中32例(39.5%)不必要的活检,但漏诊了71例恶性病变中的2例(2.8%),均为G2级DCIS。
乳腺MRI作为一种额外的诊断工具,可用于准确区分乳腺钼靶微钙化的良性和恶性,因此可能有助于减少不必要的乳腺活检。